Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny is expected to see continued growth in the fertility benefits market due to the implementation of California Senate Bill 729, its unique offerings and partnerships, and its focus on the fully-insured market. Additionally, the company's high-touch model and integration with health plans are expected to drive improved outcomes and cost savings, solidifying its market share and potential for further growth. Investors can expect Progyny to continue its strong performance and maintain its position as a leader in this growing niche market.

Bears say

Progyny is currently facing margin pressure due to increased investments in technology infrastructure, AI capabilities, and platform modernization, which has affected both operating expenses and capital expenditures. The company's membership growth may be sustainable, but renewal and expansion opportunities within the existing client base have historically varied. TrumpRx is seen as an unmanaged solution that may not cover all required medications for fertility treatment, potentially leading to uncertainty for patients. Additionally, while Progyny has experienced elevated free cash flow conversion, it may not be sustainable in the long term and the company has deliberately avoided owning a specialty pharmacy. The company's stock-based compensation expense is also expected to decline over time. Overall, the negative outlook is driven by concerns about the company's current margin pressure, potential difficulties in renewals and upsell opportunities, and uncertainty surrounding coverage for fertility treatments under TrumpRx.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.